Any prior history of or suspected current autoimmune disorders (with the exception of vitiligo, resolved childhood atopic dermatitis, prior Grave's disease now euthyroid clinically and by laboratory testing)
History of known or suspected autoimmune disease with the specific exceptions of vitiligo, resolved childhood atopic dermatitis, psoriasis not requiring systemic treatment (within the past  years), and patients with a history of Grave's disease that are now euthyroid clinically and by laboratory testing.
Patients with any history of known or suspected autoimmune disease with the specific exceptions of vitiligo, resolved childhood atopic dermatitis, psoriasis not requiring systemic treatment (within the past  years), and patients with a history of Grave's disease that are now euthyroid clinically and by laboratory testing.
Active atopic dermatitis or skin condition that disrupts the epidermis
Subject, or subjects close household contacts (defined as those who share housing or have close physical contact) have any of the following conditions during the screening and/or treatment periods:\r\n* Active or a history of atopic dermatitis, eczema or other eczematoid skin disorders that disrupt the epidermis\r\n* Other acute, chronic or exfoliative skin conditions (e.g., burns, impetigo, varicella zoster, severe acne or other open rashes or wounds) until condition resolves\r\n* Pregnant or nursing\r\n* Immunodeficient or immunosuppressed (by disease or therapy), including human immunodeficiency virus (HIV) infection
Patients with any history of known or suspected autoimmune disease with the specific exceptions of vitiligo, resolved childhood atopic dermatitis, psoriasis not requiring systemic treatment (within the past  years), and patients with a history of Grave's disease that are now euthyroid clinically and by laboratory testing
History of atopic dermatitis or active skin condition (acute, chronic, exfoliative) that disrupts the epidermis
History of or known or suspected autoimmune disease (exception[s]: subjects with vitiligo, resolved childhood atopic dermatitis, hypothyroidism, or hyperthyroidism that is clinically euthyroid at screening are allowed).
History of atopic dermatitis or active skin condition (acute, chronic, exfoliative) that disrupts the epidermis
Subject with current skin diseases that the investigator feels is not safe for study participation including but not limited to severe atopic dermatitis, cutaneous T-cell lymphoma, erythroderma
COHORT : ATOPIC DERMATITIS PATIENTS: Subjects must be aged - years
COHORT : ATOPIC DERMATITIS PATIENTS: Subjects must be co-enrolled in NIH protocol -HG-
COHORT : ATOPIC DERMATITIS PATIENTS: Subjects must have a diagnosis of atopic dermatitis on the basis of the criteria defined by UK Working Party's Diagnostic Criteria for Atopic Dermatitis
COHORT : ATOPIC DERMATITIS PATIENTS: Subjects must have a primary care provider
COHORT : ATOPIC DERMATITIS PATIENTS: Subjects must have an Objective SCORAD (SCORing Atopic Dermatitis) of >=  indicating AD severity of moderate to severe
COHORT : ATOPIC DERMATITIS PATIENTS: Prior to initiation of randomized treatment, subjects must have signs of bacterial skin infections (skin weeping, crusting, and/or pustules)
COHORT : ATOPIC DERMATITIS PATIENTS: Access to bathing facilities
COHORT : ATOPIC DERMATITIS PATIENTS: Does not meet inclusion criteria
COHORT : ATOPIC DERMATITIS PATIENTS: Any female with symptoms and/or serum hormone levels consistent with perimenopause
COHORT : ATOPIC DERMATITIS PATIENTS: Known allergic reaction to beta-lactam class drugs, lidocaine, or epinephrine
COHORT : ATOPIC DERMATITIS PATIENTS: Family history of toxic epidermal necrolysis
COHORT : ATOPIC DERMATITIS PATIENTS: Known allergic reaction to sodium hypochlorite (NaOCl)
COHORT : ATOPIC DERMATITIS PATIENTS: Use of topical or oral CAM agents within  weeks of initiation of treatment
COHORT : ATOPIC DERMATITIS PATIENTS: Subjects with known primary or acquired immunodeficiency
COHORT : ATOPIC DERMATITIS PATIENTS: Subjects receiving or planning to receive an IND agent, ultraviolet light therapy, monoclonal antibodies, or systemic immunosuppressants within  days or  half-lives (whichever is the longer time period) of initiating treatment on this protocol
COHORT : ATOPIC DERMATITIS PATIENTS: Subjects who are currently receiving or have received chemotherapy or radiation for treatment of malignancies within the previous  months
COHORT : ATOPIC DERMATITIS PATIENTS: Pregnancy or lactating
History or evidence of a physician-diagnosed chronic or recurrent inflammatory skin disease (e.g. psoriasis, eczema, atopic dermatitis, hypersensitivity) at the proposed site of administration in the past  years.
Patients with any history of known or suspected autoimmune disease with the specific exceptions of vitiligo, atopic dermatitis, or psoriasis not requiring systemic treatment.
Altered immune function, including immunodeficiency or history of immunodeficiency; eczema; history of eczema, or other eczematoid skin disorders; or those with acute, chronic or exfoliative skin conditions (e.g. atopic dermatitis, burns, impetigo, varicella zoster, severe acne, or other open rashes or wounds)
The following will not be exclusionary:\r\n* Resolved ipilimumab associated inflammatory disease\r\n* The presence of laboratory evidence of autoimmune disease (e.g., positive antinuclear antibody [ANA] titer) without associated symptoms\r\n* Subjects with vitiligo, thyroiditis, or atopic dermatitis, but otherwise not meeting this criterion may be enrolled; individual cases can be discussed with the sponsor
Has an active autoimmune disease requiring immunosuppression with the exception of subjects with isolated vitiligo, resolved childhood asthma or atopic dermatitis, controlled hypoadrenalism or hypopituitarism, and euthyroid patients with a history of Grave's disease.
History of or known or suspected autoimmune disease (exception: vitiligo, resolved childhood atopic dermatitis, and history of Grave's disease that is euthyroid clinically and by laboratory testing at Screening)
Patients with history of autoimmune disease with certain exceptions such as vitiligo, resolved chilhood atopic dermatitis, psoriasis not requiring systemic therapy within the past  years, patients with history of Grave's disease that are now euthyroid clinically and by lab testing
History of atopic dermatitis or active skin condition (acute, chronic, exfoliative) that disrupts the epidermis
Active widespread skin disorders such as psoriasis, chronic urticarial or dermatitis
History of atopic dermatitis or active skin condition (acute, chronic, exfoliative) that disrupts the epidermis
History of atopic dermatitis or active skin condition (acute, chronic, exfoliative) that disrupts the epidermis
Patients must not have active eczema, atopic dermatitis, or other exfoliative skin conditions (e.g., burns, impetigo, varicella zoster, severe acne, contact dermatitis, psoriasis, herpes or other open rashes or wounds)
Have preexisting Grade ? skin disorder (for example, erythema, dermatitis).
History of or known or suspected autoimmune disease (exception[s]: subjects with vitiligo, resolved childhood atopic dermatitis, hypothyroidism, or hyperthyroidism that is clinically euthyroid at screening are allowed)
History of autoimmune disease with certain exceptions such as vitiligo, resolved childhood atopic dermatitis, psoriasis not requiring systemic therapy within the past  years, patients with history of Grave's disease that are now euthyroid clinically and by lab testing
Patients must not have any of the following serious concomitant skin disorders that, in the investigators opinion, could interfere with assessment of EGFRI induced skin toxicity: atopic dermatitis (eczema), contact dermatitis, psoriasis, rosacea, severe photosensitivity, scleroderma, steroid-induced acne, xerosis
Any prior history of or suspected current autoimmune disorders (with the exception of vitiligo, resolved childhood atopic dermatitis, prior Grave's disease)
Any dermatological condition that in the opinion of the investigator will affect the absorption of the study medication, e.g. Atopic Dermatitis, etc.
Patients with any history of known or suspected autoimmune disease with the specific exceptions of vitiligo, resolved childhood atopic dermatitis, psoriasis not requiring systemic treatment within the past  years, and patients with a history of Grave's disease that are now euthyroid clinically and by laboratory testing.
History of known or suspected autoimmune disease with the specific exceptions of vitiligo, atopic dermatitis, or psoriasis not requiring systemic treatment. (Parts C, D and E only).
